TAIKO PHARMA, Net Income Forecast for the Fiscal Year Revised Upward by 50%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Wed Aug 20, 2025 3:30 pm JST Revision

4574 TAIKO PHARMACEUTICAL CO., LTD. 【J-GAAP】

Guidance Update Report

TAIKO PHARMACEUTICAL CO., LTD. <4574> [TSE Prime] announced a performance revision after the market closed on August 20th (15:30). The consolidated net income forecast for the fiscal year ending December 2025 has been revised upward 50.0%, from the previous forecast of 300 million yen to 450 million yen (compared to 898 million yen in the previous period), and the declining rate is expected to decrease from 66.6% to 49.9%.

Based on the upwardly revised full-year plan announced by the company, our calculation indicates that the July to December period (second half) consolidated net income is expected to increase 8.1 times, from the previous forecast of 21 million yen to 171 million yen (compared to 134 million yen in the same period of the previous year), turning to a 27.6% increase in the consolidated net income outlook.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2025 Prev	3,888	169	180	21	0.4	－	Aug 8, 2025	J-GAAP
Jul - Dec, 2025 New	3,888	169	180	171	3.4	－	Aug 20, 2025	J-GAAP
Revision Rate	0.0%	0.0%	0.0%	+714.3%	+709.5%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2025 Prev	6,300	215	200	300	6.0	－	Feb 13, 2025	J-GAAP
Dec, 2025 New	6,300	215	200	450	9.0	－	Aug 20, 2025	J-GAAP
Revision Rate	0.0%	0.0%	0.0%	+50.0%	+50.1%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2024	3,432	147	160	134	2.7	0	Feb 13, 2025	J-GAAP
Jul - Dec, 2025 Guidance	3,888	169	180	171	3.4	－	Aug 20, 2025	J-GAAP
YoY	+13.3%	+15.0%	+12.5%	+27.6%	+27.3%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	6,120	-1,005	-1,248	-3,611	-76.3	0	Feb 9, 2024	J-GAAP
Dec, 2024	6,292	629	688	898	17.9	0	Feb 13, 2025	J-GAAP
Dec, 2025 Guidance	6,300	215	200	450	9.0	－	Aug 20, 2025	J-GAAP
YoY	+0.1%	-65.8%	-70.9%	-49.9%	-49.9%